December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Serena Di Cosimo: The prognostic value of residual tumor biology during neoadjuvant treatment in patients with HER2+ breast cancer
Dec 24, 2024, 07:42

Serena Di Cosimo: The prognostic value of residual tumor biology during neoadjuvant treatment in patients with HER2+ breast cancer

Serena Di Cosimo, Medical Director at IRCCS Foundation National Cancer Institute, Milan, shared a recent article on LinkedIn:

“This article published in Annals of Oncology explores the prognostic value of the biology of residual tumor disease and changes in gene expression during neoadjuvant treatment in patients with early HER2-positive breast cancer.

The results are the result of an international collaboration involving numerous researchers from all over the world.

I take this opportunity to publicly greet them all and to thank the Strategic Direction of the National Cancer Institute, the AIRC Foundation for Cancer Research and, above all, the women treated for HER2-positive breast cancer and their loved ones, who have made and make the research I am involved in possible.

I wish you all a Merry Christmas.”

Title: Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2+ early breast cancer (EBC)

Authors: Aranzazu Fernandez-Martinez, Maki Tanioka, Sung Gwe Ahn, Paola Zagami, Tomás Pascual, Mattia Rediti, Gong Tang, Katherine A. Hoadley, David Venet, Naim U. Rashid, Patricia A. Spears, Serena Di Cosimo, Evandro de Azambuja, Anup Choudhury, Priya Rastogi, Md N. Islam, Javier Cortes, Antonio Llombart-Cussac, Sandra M. Swain, Christos Sotiriou, Aleix Prat, Charles M. Perou and Lisa A. Carey

Serena Di Cosimo

For more updates, follow OncoDaily.